Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole + mosapride
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Esomeprazole + mosapride is a fixed-dose combination of two small molecule drugs used primarily for the treatment of gastroesophageal reflux disease (GERD) and related gastrointestinal disorders. Esomeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. Mosapride is a selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist, classified as a prokinetic agent, which enhances gastrointestinal motility by increasing acetylcholine release from parasympathetic nerve endings, thereby stimulating esophageal peristalsis and accelerating gastric emptying[1][3][6]. The combination has been studied to determine if adding mosapride to esomeprazole improves symptom control or esophageal function in GERD patients; while some studies show improved motility parameters, most evidence suggests no significant additional benefit for symptom resolution compared to PPI monotherapy[1][3][6].
- Other names
- esomeprazole magnesium + mosapride citrate
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)HTR4 (5-Hydroxytryptamine receptor 4)
Beyond the preview
Go deeper on esomeprazole + mosapride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole + mosapride.